AU2018363686B2 - Process for preparing large size isoxazoline particles - Google Patents

Process for preparing large size isoxazoline particles Download PDF

Info

Publication number
AU2018363686B2
AU2018363686B2 AU2018363686A AU2018363686A AU2018363686B2 AU 2018363686 B2 AU2018363686 B2 AU 2018363686B2 AU 2018363686 A AU2018363686 A AU 2018363686A AU 2018363686 A AU2018363686 A AU 2018363686A AU 2018363686 B2 AU2018363686 B2 AU 2018363686B2
Authority
AU
Australia
Prior art keywords
isoxazoline compound
particles
isoxazoline
particle size
crystallizer vessel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018363686A
Other languages
English (en)
Other versions
AU2018363686A1 (en
Inventor
Aaron Cote
Athanas KOYNOV
Luke Ryan SCHENCK
George X. ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of AU2018363686A1 publication Critical patent/AU2018363686A1/en
Application granted granted Critical
Publication of AU2018363686B2 publication Critical patent/AU2018363686B2/en
Priority to AU2024201160A priority Critical patent/AU2024201160A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Insects & Arthropods (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AU2018363686A 2017-11-07 2018-11-06 Process for preparing large size isoxazoline particles Active AU2018363686B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201160A AU2024201160A1 (en) 2017-11-07 2024-02-22 Process for preparing large size isoxazoline particles

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762582381P 2017-11-07 2017-11-07
US62/582,381 2017-11-07
US201762608904P 2017-12-21 2017-12-21
US62/608,904 2017-12-21
PCT/EP2018/080230 WO2019091940A1 (en) 2017-11-07 2018-11-06 Process for preparing large size isoxazoline particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201160A Division AU2024201160A1 (en) 2017-11-07 2024-02-22 Process for preparing large size isoxazoline particles

Publications (2)

Publication Number Publication Date
AU2018363686A1 AU2018363686A1 (en) 2020-05-07
AU2018363686B2 true AU2018363686B2 (en) 2023-11-23

Family

ID=64172503

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018363686A Active AU2018363686B2 (en) 2017-11-07 2018-11-06 Process for preparing large size isoxazoline particles
AU2024201160A Pending AU2024201160A1 (en) 2017-11-07 2024-02-22 Process for preparing large size isoxazoline particles

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201160A Pending AU2024201160A1 (en) 2017-11-07 2024-02-22 Process for preparing large size isoxazoline particles

Country Status (16)

Country Link
US (2) US11858904B2 (enExample)
EP (1) EP3707129A1 (enExample)
JP (3) JP7446222B2 (enExample)
KR (2) KR102694519B1 (enExample)
CN (1) CN111295375B (enExample)
AU (2) AU2018363686B2 (enExample)
BR (1) BR112020008848A2 (enExample)
CA (1) CA3081653A1 (enExample)
CL (1) CL2020001172A1 (enExample)
CO (1) CO2020006258A2 (enExample)
IL (1) IL274075A (enExample)
MX (3) MX2020004693A (enExample)
PE (1) PE20210170A1 (enExample)
PH (1) PH12020500586A1 (enExample)
UA (1) UA127892C2 (enExample)
WO (1) WO2019091940A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102606187B1 (ko) * 2017-11-07 2023-11-23 인터벳 인터내셔널 비.브이. 주사가능한 이속사졸린 제약 조성물 및 그의 기생충 침입에 대한 용도
US12497370B2 (en) 2019-12-18 2025-12-16 Elanco Tiergesundheit Ag Isoxazoline derivatives
CN115666514A (zh) 2020-05-20 2023-01-31 英特维特国际股份有限公司 可注射的药物组合物及其用途
CA3185969A1 (en) 2020-07-24 2022-01-27 Jean Marie Defauw Process for making an isoxazoline compound and intermediate thereof
CN112724095A (zh) * 2020-09-25 2021-04-30 安徽省公众检验研究院有限公司 氟雷拉钠晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308857A1 (en) * 2008-07-09 2011-04-13 Nissan Chemical Industries, Ltd. Process for production of isoxazoline-substituted benzoic acid amide compound
WO2011149749A1 (en) * 2010-05-27 2011-12-01 E.I. Du Pont De Nemours And Company Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
US20140121194A1 (en) * 2012-11-01 2014-05-01 Sumitomo Chemical Company, Limited Method for administering agent for controlling ectoparasite to dog

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508140B1 (pt) 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
DK2182945T3 (en) 2007-06-27 2015-11-16 Du Pont PROCEDURE TO COMBAT PESTS WITH ANIMALS
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
WO2009063910A1 (ja) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. 光学活性イソキサゾリン化合物の触媒的不斉合成方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
CA2747060A1 (en) 2008-12-18 2010-07-15 Novartis Ag Isoxazolines derivatives and their use as pesticide
RU2518462C2 (ru) 2008-12-19 2014-06-10 Новартис Аг Органические соединения
JP5801295B2 (ja) * 2009-06-24 2015-10-28 メルク・シャープ・エンド・ドーム・ベー・フェー アセナピンを含有する注射可能な配合物およびそれを用いた処置方法
JP5679102B2 (ja) 2009-08-03 2015-03-04 日産化学工業株式会社 ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
CN105121416B (zh) 2013-02-14 2018-12-04 日产化学工业株式会社 异噁唑啉取代苯甲酰胺化合物的结晶性多晶型物及其制造方法
JP2015028006A (ja) 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
CN105579029B (zh) 2013-09-30 2019-03-05 硕腾服务有限责任公司 长效螺异恶唑啉制剂
HUE072822T2 (hu) 2013-12-20 2025-12-28 Intervet Int B V Izoxazolin kompozíciók és azok felhasználása parazita fertõzések megelõzésében vagy kezelésében állatokban
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
KR102593069B1 (ko) 2015-04-08 2023-10-23 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 이속사졸린 활성제를 포함하는 서방형 주사 제형, 이의 방법 및 용도
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
KR102606187B1 (ko) 2017-11-07 2023-11-23 인터벳 인터내셔널 비.브이. 주사가능한 이속사졸린 제약 조성물 및 그의 기생충 침입에 대한 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308857A1 (en) * 2008-07-09 2011-04-13 Nissan Chemical Industries, Ltd. Process for production of isoxazoline-substituted benzoic acid amide compound
WO2011149749A1 (en) * 2010-05-27 2011-12-01 E.I. Du Pont De Nemours And Company Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
US20140121194A1 (en) * 2012-11-01 2014-05-01 Sumitomo Chemical Company, Limited Method for administering agent for controlling ectoparasite to dog

Also Published As

Publication number Publication date
KR102819993B1 (ko) 2025-06-11
US11858904B2 (en) 2024-01-02
KR20200085295A (ko) 2020-07-14
UA127892C2 (uk) 2024-02-07
MX2020004693A (es) 2020-08-20
AU2024201160A1 (en) 2024-03-14
IL274075A (en) 2020-06-30
JP2021501755A (ja) 2021-01-21
NZ765172A (en) 2024-05-31
US20240246921A1 (en) 2024-07-25
KR102694519B1 (ko) 2024-08-13
BR112020008848A2 (pt) 2020-10-20
CN111295375A (zh) 2020-06-16
US20200331867A1 (en) 2020-10-22
JP7446222B2 (ja) 2024-03-08
CO2020006258A2 (es) 2020-05-29
JP2023099059A (ja) 2023-07-11
WO2019091940A1 (en) 2019-05-16
PE20210170A1 (es) 2021-01-29
CN111295375B (zh) 2025-06-24
CA3081653A1 (en) 2019-05-16
KR20240125076A (ko) 2024-08-19
JP7578752B2 (ja) 2024-11-06
MX2025006001A (es) 2025-07-01
EP3707129A1 (en) 2020-09-16
CL2020001172A1 (es) 2020-10-23
AU2018363686A1 (en) 2020-05-07
MX2023014279A (es) 2024-07-10
RU2020117583A3 (enExample) 2021-12-24
PH12020500586A1 (en) 2021-06-21
RU2020117583A (ru) 2021-12-08
JP2024010042A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
AU2018363686B2 (en) Process for preparing large size isoxazoline particles
US9283210B2 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
US8067423B2 (en) Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof
DE69521645T2 (de) Pyridinderivate
US20130211099A1 (en) Asenapine maleate
JP2024010042A5 (enExample)
WO2012066565A2 (en) Asenapine maleate amorphous and crystalline form and process for preparation thereof
CN107698412A (zh) 基于气动雾化‑反溶剂结晶的炸药共晶体制备方法
RU2797561C2 (ru) Способ получения частиц изоксазолина большого размера
TW202200564A (zh) ４－（２－（吡咯啶－１－基）－４－（三氟甲基）苄基）哌－１－甲酸１，１，１，３，３，３－六氟丙－２－基酯之製造
US20050143577A1 (en) Method for producing the automeric form of (1) of 2, 4, 6-trianilino-p- (carbo-2'-ethyl-heyk-1'oxyl)-1, 2, 5-triazine
KR101573616B1 (ko) 구아닐우레아 디니트라미드의 재결정에 의한 형상 및 입도 조절방법
JPH02240079A (ja) 化学的方法
US20150225380A1 (en) Novel Method to Obtain Olmesartan Medoxomil With Reduced Particle Size
NZ805055A (en) Process for preparing large size isoxazoline particles
NZ765172B2 (en) Process for preparing large size isoxazoline particles
KR102833486B1 (ko) 디하이드록실암모늄 5,5'-비스테트라졸-1,1'-디올레이트 재결정화 방법 및 그에 의해 재결정화된 tkx-50
JP7486763B2 (ja) 安定なアジルサルタン微細結晶の製造方法
WO2017134679A1 (en) Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
WO2004103999A1 (en) AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
CN117263875A (zh) 一种戊唑醇晶体及其连续结晶方法和应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)